Results 91 to 100 of about 2,738 (166)

Early low-density lipoprotein apheresis for steroid-resistant minimal change disease with acute kidney injury: a case report. [PDF]

CEN Case Rep
Hiramatsu M, Inoue M, Kamegai N, Michiya O, Yamamoto J.   +4 more
europepmc   +1 more source

Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events? [PDF]

J Cardiovasc Dev Dis, 2020
Julius U, Kuss S, Tselmin S, Schatz U, Bornstein SR.   +4 more
europepmc   +1 more source

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. [PDF]

Med Sci Monit, 2021
Matta A, Bongard V, Bouisset F, Taraszkiewicz D, Rabès JP, Ferrières J.   +5 more
europepmc   +1 more source

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions. [PDF]

Oxid Med Cell Longev, 2020
Mickiewicz A, Kreft E, Kuchta A, Wieczorek E, Marlęga J, Ćwiklińska A, Paprzycka M, Gruchała M, Fijałkowski M, Jankowski M.   +9 more
europepmc   +1 more source

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease. [PDF]

J Clin Apher
Röseler T, Kayser D, Schlieper G, Bernhardt WM.   +3 more
europepmc   +1 more source

Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs. [PDF]

Int J Mol Sci
Krzesińska A, Marlęga-Linert J, Chyła-Danił G, Marcinkowska M, Rogowska P, Stumska K, Fijałkowski M, Gruchała M, Jankowski M, Mickiewicz A, Kuchta A.   +10 more
europepmc   +1 more source

Prosthetic Gait Achievement in an Elderly Patient with Chronic Limb-threatening Ischemia and High Complications Using a Novel Lipoprotein Apheresis. [PDF]

Prog Rehabil Med
Tashima H, Ochi M, Hori R, Hachisuka A, Itoh H, Matsushima Y, Saeki S.   +6 more
europepmc   +1 more source

Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review. [PDF]

Thromb J
Guan M, Wang H, Wang F, Liang S, Ling L, Wang B, Zhang L.   +6 more
europepmc   +1 more source

Improvement of oxidative stress status by lipoprotein apheresis in Chinese patients with familial hypercholesterolemia. [PDF]

J Clin Lab Anal, 2020
Wen J, Dong Q, Liu G, Gao Y, Li XL, Jin JL, Li JJ, Guo YL.   +7 more
europepmc   +1 more source